Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20768034 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL19229666 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL712340 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL29352086 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL4578013 | 0.99 | CETP (0.98) | CETP | |
| SCHEMBL4578018 | 0.99 | CETP (0.98) | CETP | |
| SCHEMBL18027493 | 0.93 | CETP (0.88) | CETP | |
| SCHEMBL2610427 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL20768008 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL20768006 | 0.90 | CETP (1.00) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11549142-B2 | CETP inhibitors for therapeutic use | HOFFMANN-LA ROCHE INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3795695-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY | F. Hoffmann-La Roche AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| US-20210017597-A1 | CETP INHIBITORS FOR THERAPEUTIC USE | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-1828137-B1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-1828137-B1 | 4-CYCLOALKYL-SUBSTITUTED TETRAHYDROCHINOLINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11549142-B2 | CETP inhibitors for therapeutic use | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | CETP 311/4885 |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | CETP, MTTP, HDLBP | CETP 1/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CETP 10/4885 |
| US-20210017597-A1 | CETP INHIBITORS FOR THERAPEUTIC USE | CETP, HDLBP, APOB | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.